CoChat
Sign Up
Cited by 372Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells

Open access
Lagace, Thomas A.·2014·Current Opinion in Lipidology
DOI 10.1097/mol.0000000000000114PMC PMC4166010
Open this paper in CoChat — free account

Abstract

PURPOSE OF REVIEW: Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to LDL receptor (LDLR) and targets it for lysosomal degradation in cells. Decreased hepatic clearance of plasma LDL-cholesterol is the primary gauge of PCSK9 activity in humans; however, PCSK9's evolutionary role may extend to other lipoprotein classes and processes. This review highlights studies that are providing novel insights into physiological regulation of PCSK9 transcription and plasma PCSK9 activity. RECENT FINDINGS: Recent studies indicate that circulating PCSK9 binds to apolipoprotein B100 on LDL particles, which in turn inhibits PCSK9's ability to bind to cell surface LDLRs. Negative feedback of secreted PCSK9 activity by LDL could serve to increase plasma excursion of triglyceride-rich lipoproteins and monitor lipoprotein remodeling. Recent findings have identified hepatocyte nuclear factor-1α as a key transcriptional regulator that cooperates with sterol regulatory element-binding protein-2 to control PCSK9 expression in hepatocytes in response to nutritional and hormonal inputs, as well as acute inflammation. SUMMARY: PCSK9 is an established target for cholesterol-lowering therapies. Further study of PCSK9 regulatory mechanisms may identify additional control points for pharmacological inhibition of PCSK9-mediated LDLR degradation. PCSK9 function could reflect ancient roles in the fasting-feeding cycle and in linking lipoprotein metabolism with innate immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mol.0000000000000114

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Box 1 no caption available
Box 1 no caption availableCC BY-NC-ND · PubMed Central
FIGURE 1 Regulation of PCSK9-mediated LDLR degradation by plasma apolipoprotein B100. Two pathways exist in hepatic cells for degradation of LDLR directed by PCSK9 (red arrows). PCSK9 can bind to LDLR in the luminal secretory compartment and target LDLR to lysosomes in vesicles emanating from the trans-Golgi. Alternatively, secreted PCSK9 can bind to LDLR on the cell surface and be internalized with LDLRs in endocytic vesicles. Unlike ligands LDL (apoB100) and VLDL (apoE) that release from the LDLR within acidic early endosomes, PCSK9 remains bound and prevents LDLR recycling to the cell surface, redirecting the receptor to lysosomes in which both PCSK9 and LDLR are degraded. Within the circulation PCSK9 can bind to apoB100 on LDL particles, but not to apoB100 on VLDL particles. The binding site on apoB100 may be unmasked by lipolysis of triglycerides on VLDL particles or other lipid modifications and conversion of VLDL to the short-lived IDL, which is further converted to LDL. IDL, intermediate density lipoprotein.
FIGURE 1 Regulation of PCSK9-mediated LDLR degradation by plasma apolipoprotein B100. Two pathways exist in hepatic cells for degradation of LDLR directed by PCSK9 (red arrows). PCSK9 can bind to LDLR in the luminal secretory compartment and target LDLR to lysosomes in vesicles emanating from the trans-Golgi. Alternatively, secreted PCSK9 can bind to LDLR on the cell surface and be internalized with LDLRs in endocytic vesicles. Unlike ligands LDL (apoB100) and VLDL (apoE) that release from the LDLR within acidic early endosomes, PCSK9 remains bound and prevents LDLR recycling to the cell surface, redirecting the receptor to lysosomes in which both PCSK9 and LDLR are degraded. Within the circulation PCSK9 can bind to apoB100 on LDL particles, but not to apoB100 on VLDL particles. The binding site on apoB100 may be unmasked by lipolysis of triglycerides on VLDL particles or other lipid modifications and conversion of VLDL to the short-lived IDL, which is further converted to LDL. IDL, intermediate density lipoprotein.CC BY-NC-ND · PubMed Central
FIGURE 2 Model of proprotein convertase subtilisin/kexin type-9 dysregulation under conditions of elevated plasma proprotein convertase subtilisin/kexin type-9 concentration. At low concentrations of plasma PCSK9 (top panel), such as may be present in a low nutrient environment, PCSK9 senses the conversion of VLDL to LDL in the plasma compartment through its ability to bind to LDL. When plasma LDL is low relative to hepatic VLDL production and PCSK9 secretion, the majority of circulating PCSK9 is in a free active form and directs hepatic LDLR degradation. As the LDL/VLDL ratio increases, and as plasma PCSK9 levels decline in fasting, a progressively higher percentage of plasma PCSK9 becomes LDL-bound and inactive, thereby promoting hepatic clearance of LDL. At high concentrations of plasma PCSK9 and LDL (lower panel) PCSK9 activity is less sensitive to the VLDL-to-LDL conversion, and the regulatory pool of LDL-apoB100 is mainly a function of hepatic LDL clearance. Due to a relatively low binding affinity to LDL (Kd∼ 300 nM) [42▪▪], negative feedback control of PCSK9 activity becomes dysregulated at high PCSK9 levels. Although a higher percentage of total plasma PCSK9 may bind to LDL under conditions of hypercholesterolemia, because of increased hepatic PCSK9 secretion there remains a large component of free and active PCSK9 in the circulation.
FIGURE 2 Model of proprotein convertase subtilisin/kexin type-9 dysregulation under conditions of elevated plasma proprotein convertase subtilisin/kexin type-9 concentration. At low concentrations of plasma PCSK9 (top panel), such as may be present in a low nutrient environment, PCSK9 senses the conversion of VLDL to LDL in the plasma compartment through its ability to bind to LDL. When plasma LDL is low relative to hepatic VLDL production and PCSK9 secretion, the majority of circulating PCSK9 is in a free active form and directs hepatic LDLR degradation. As the LDL/VLDL ratio increases, and as plasma PCSK9 levels decline in fasting, a progressively higher percentage of plasma PCSK9 becomes LDL-bound and inactive, thereby promoting hepatic clearance of LDL. At high concentrations of plasma PCSK9 and LDL (lower panel) PCSK9 activity is less sensitive to the VLDL-to-LDL conversion, and the regulatory pool of LDL-apoB100 is mainly a function of hepatic LDL clearance. Due to a relatively low binding affinity to LDL (Kd∼ 300 nM) [42▪▪], negative feedback control of PCSK9 activity becomes dysregulated at high PCSK9 levels. Although a higher percentage of total plasma PCSK9 may bind to LDL under conditions of hypercholesterolemia, because of increased hepatic PCSK9 secretion there remains a large component of free and active PCSK9 in the circulation.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 57

  1. Abifadel, 2009, Hum Mutat, 30, 520, 10.1002/humu.20882 · DOI
  2. Abifadel, 2003, Nat Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  3. Lagace, 2006, J Clin Invest, 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  4. Zhang, 2007, J Biol Chem, 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  5. Benjannet, 2004, J Biol Chem, 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  6. Kwon, 2008, Proc Natl Acad Sci U S A, 105, 1820, 10.1073/pnas.0712064105 · DOI · Paper page
  7. Chan, 2009, Proc Natl Acad Sci U S A, 106, 9820, 10.1073/pnas.0903849106 · DOI · Paper page
  8. Poirier, 2013, Drug Des Devel Ther, 7, 1135
  9. Stein, 2013, Curr Atheroscler Rep, 15, 310, 10.1007/s11883-013-0310-3 · DOI
  10. Seidah, 2003, Proc Natl Acad Sci U S A, 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  11. Seidah, 2013, J Biol Chem, 288, 21473, 10.1074/jbc.R113.481549 · DOI
  12. Cunningham, 2007, Nat Struct Mol Biol, 14, 413, 10.1038/nsmb1235 · DOI · Paper page
  13. McNutt, 2007, J Biol Chem, 282, 20799, 10.1074/jbc.C700095200 · DOI · Paper page
  14. Grefhorst, 2008, J Lipid Res, 49, 1303, 10.1194/jlr.M800027-JLR200 · DOI · Paper page
  15. Poirier, 2009, J Biol Chem, 284, 28856, 10.1074/jbc.M109.037085 · DOI · Paper page
  16. Zhang, 2008, Proc Natl Acad Sci U S A, 105, 13045, 10.1073/pnas.0806312105 · DOI · Paper page
  17. Lo Surdo, 2011, EMBO Rep, 12, 1300, 10.1038/embor.2011.205 · DOI · Paper page
  18. Tavori, 2013, Circulation, 127, 2403, 10.1161/CIRCULATIONAHA.113.001592 · DOI · Paper page
  19. Dubuc, 2004, Arterioscler Thromb Vasc Biol, 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  20. JeongJeong, 2008, J Lipid Res, 49, 399, 10.1194/jlr.M700443-JLR200 · DOI · Paper page
  21. Brown, 1997, Cell, 89, 331, 10.1016/S0092-8674(00)80213-5 · DOI · Paper page
  22. Browning, 2010, J Lipid Res, 51, 3359, 10.1194/jlr.P009860 · DOI
  23. Persson, 2010, Arterioscler Thromb Vasc Biol, 30, 2666, 10.1161/ATVBAHA.110.214130 · DOI · Paper page
  24. Horton, 2007, Trends Biochem Sci, 2, 71, 10.1016/j.tibs.2006.12.008 · DOI · Paper page
  25. Twisk, 2000, J Clin Invest, 105, 521, 10.1172/JCI8623 · DOI
  26. Blasiole, 2008, J Biol Chem, 283, 11374, 10.1074/jbc.M710457200 · DOI · Paper page
  27. Lambert, 2006, Endocrinology, 147, 4985, 10.1210/en.2006-0098 · DOI
  28. Herbert, 2010, Arterioscler Thromb Vasc Biol, 30, 1333, 10.1161/ATVBAHA.110.204040 · DOI
  29. Sun, 2012, Arterioscler Thromb Vasc Biol, 32, 1585, 10.1161/ATVBAHA.112.250043 · DOI
  30. Li, 2009, J Biol Chem, 284, 28885, 10.1074/jbc.M109.052407 · DOI
  31. Armendariz, 2009, Curr Opin Lipidol, 20, 106, 10.1097/MOL.0b013e3283295ee9 · DOI
  32. Dong, 2010, J Lipid Res, 51, 1486, 10.1194/jlr.M003566 · DOI
  33. Ai, 2012, J Clin Invest, 122, 1262, 10.1172/JCI61919 · DOI
  34. Shimomura, 2000, Mol Cell, 6, 77, 10.1016/S1097-2765(00)00009-5 · DOI
  35. Laplante, 2012, Cell, 149, 274, 10.1016/j.cell.2012.03.017 · DOI · Paper page
  36. Lakoski, 2009, J Clin Endocrinol Metab, 94, 2537, 10.1210/jc.2009-0141 · DOI · Paper page
  37. Kwakernaak, 2014, Clin Biochem, 47, 679, 10.1016/j.clinbiochem.2014.03.008 · DOI
  38. Benjannet, 2010, J Biol Chem, 285, 40965, 10.1074/jbc.M110.154815 · DOI
  39. Holla, 2011, Biochem Biophys Res Commun, 406, 234, 10.1016/j.bbrc.2011.02.023 · DOI
  40. Benjannet, 2006, J Biol Chem, 281, 30561, 10.1074/jbc.M606495200 · DOI · Paper page
  41. Han, 2014, J Lipid Res, 55, 1505, 10.1194/jlr.M049346 · DOI
  42. Essalmani, 2011, J Biol Chem, 286, 4257, 10.1074/jbc.M110.192104 · DOI · Paper page
  43. Azzam, 2012, Trends Endocrinol Metab, 23, 169, 10.1016/j.tem.2012.02.001 · DOI · Paper page
  44. Vreugdenhil, 2001, J Clin Invest, 107, 225, 10.1172/JCI10832 · DOI
  45. Feingold, 2008, Biochem Biophys Res Commun, 374, 341, 10.1016/j.bbrc.2008.07.023 · DOI
  46. Xiao, 2012, Pharmacol Rep, 64, 889, 10.1016/S1734-1140(12)70883-6 · DOI
  47. Barter, 2003, Arterioscler Thromb Vasc Biol, 23, 160, 10.1161/01.ATV.0000054658.91146.64 · DOI
  48. Annema, 2012, Nutr Metab (Lond), 9, 25, 10.1186/1743-7075-9-25 · DOI
  49. Moore, 2013, Nat Rev Immunol, 13, 709, 10.1038/nri3520 · DOI · Paper page
  50. Le May, 2013, Arterioscler Thromb Vasc Biol, 33, 1484, 10.1161/ATVBAHA.112.300263 · DOI
  51. Van der Veen, 2009, J Biol Chem, 284, 19211, 10.1074/jbc.M109.014860 · DOI
  52. Brown, 1997, Nature, 388, 629, 10.1038/41672 · DOI · Paper page
  53. Brown, 1981, N Engl J Med, 305, 515, 10.1056/NEJM198108273050909 · DOI
  54. Raal, 2013, J Am Heart Assoc, 2, e000028, 10.1161/JAHA.112.000028 · DOI
  55. Richard, 2012, Br J Nutr, 107, 705, 10.1017/S0007114511003436 · DOI
  56. Raal, 2014, J Am Coll Cardiol, 63, 1278, 10.1016/j.jacc.2014.01.006 · DOI
  57. Koren, 2014, J Am Coll Cardiol, 63, 2531, 10.1016/j.jacc.2014.03.018 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Lagace, T. A.
Affiliations
Ottawa Heart Institute (CA)
Corresponding author
Lagace, Thomas A.
ORCID
Lagace, Thomas A.
Venue
Current Opinion in Lipidology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2014-10
Volume
25
Issue
5
Pages
387-393
ISSN
0957-9672 (ISSN-L)
DOI
10.1097/mol.0000000000000114
PMC
PMC4166010
OpenAlex
W2036304437
Cited by
372
References
7
Citations by year
2026: 28 · 2025: 41 · 2024: 55 · 2023: 37 · 2022: 38 · 2021: 36 · 2020: 36 · 2019: 25 · 2018: 25 · 2017: 20 · 2016: 18 · 2015: 13
FWCI
3.21
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Current Opinion in Lipidology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Heart and Stroke Foundation of Canada
  • Canadian Institutes of Health Research (106462_1)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
PCSK9, LDL receptor, LDLR degradation, lysosomal degradation, apolipoprotein B-100, triglyceride-rich lipoproteins, lipoprotein remodeling, HNF1A, SREBP2, PCSK9 inhibitors, innate immunity, lipoprotein metabolism
MeSH terms
Proprotein Convertase 9, Apolipoproteins B, Gene Expression Regulation, Humans, Immunity, Innate, Inflammation, Lipoproteins, LDL, Lysosomes, Protein Binding, Receptors, LDL, Serine Endopeptidases, Hepatocytes, Proprotein Convertases, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review